Milurit (Allopurinol)

Allopurinol, the active ingredient in Milurit, is a xanthine oxidase inhibitor presented as an oral tablet for oral use. It reduces uric acid production and is employed in the management of gout, chronic hyperuricemia, and to prevent tumor lysis syndrome in oncology patients. GNH USA supplies Milurit as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Milurit, a xanthine oxidase inhibitor, is indicated for conditions related to excess uric acid production.

Gout: lowers serum urate levels to prevent acute attacks and tophi formation. Hyperuricemia: maintains target uric acid concentrations in chronic elevation. Prevention of tumor lysis syndrome: reduces uric acid surge during rapid cancer cell breakdown.

Adverse reactions may occur with any dosage form of allopurinol.

Common Side Effects: - Rash or mild skin irritation - Nausea or vomiting - Diarrhoea - Abdominal discomfort - Elevated liver enzymes - Mild headache

Serious or Rare Side Effects: - Severe hypersensitivity reactions (Stevens‑Johnson syndrome, toxic epidermal necrolysis) - Agranulocytosis or severe neutropenia - Acute interstitial nephritis - Hepatotoxicity - Severe cutaneous adverse reactions (SCARs)

Allopurinol requires careful monitoring in several clinical situations.

Renal impairment: dose may need adjustment and renal function should be monitored. Hypersensitivity history: avoid if the patient has experienced severe reactions to allopurinol. Concurrent chemotherapy: monitor uric acid closely during tumor lysis prophylaxis. Pregnancy and lactation: risk–benefit assessment required due to limited data. Drug interactions: review concomitant medications for potential interactions. Store at ambient temperature: keep below 25 °C, retain in original packaging, protect from moisture and direct sunlight.

Allopurinol can alter the pharmacokinetics of several agents, necessitating vigilance.

Major Interactions (Avoid): - Azathioprine or mercaptopurine: risk of severe bone‑marrow suppression. - Warfarin: increased anticoagulant effect, monitor INR closely. - Cyclosporine: heightened nephrotoxicity risk. - Thiazide diuretics: may potentiate hypersensitivity reactions. - High‑dose vitamin C: can increase oxalate stone formation.

Moderate Interactions (Monitor Closely): - NSAIDs: may enhance renal toxicity. - Theophylline: reduced clearance, watch for toxicity. - ACE inhibitors: monitor renal function and potassium levels. - Allopurinol with other urate‑lowering agents: adjust dose to avoid over‑lowering uric acid.